Navigation Links
MADIT-CRT Trial Meets Primary Endpoint
Date:6/23/2009

dvances in indications in the CRM space through trials like MADIT-CRT. More than 80 percent of U.S. patients who receive an ICD or CRT-D were first indicated for this therapy by a clinical trial sponsored by Boston Scientific or its predecessors(3)."

MADIT-CRT is providing insight into the potential of CRT-D therapy to intervene earlier in the natural progression of heart failure. Currently, patients must be in NYHA Class III/IV heart failure to be indicated for CRT-D therapy. However, approximately 70 percent of all heart failure patients in the U.S. fall into Class I or II. Nearly 22 million people worldwide, including approximately 5.5 million Americans, suffer from some form of heart failure.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projec
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture (EDC) Clinical Trial Survey
2. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
3. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
4. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
5. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
6. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
7. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
8. New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
9. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
10. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... REDMOND, Washington , 29. Juli 2015 ... deutschen Diabeteszentrums wurde festgestellt, dass die tägliche ... von Nutraceutix die menschliche Darmflora anreichert und ... Insulinsekretion erhöhen. Die Studie umfasste die tägliche ... (ATCC-Stamm SD-5865) in Tablettenform unter Verwendung der ...
(Date:7/29/2015)... 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ) ... interest assignment agreement (the "Agreement") in which it has ... ) with up to $200 million in revenue interest ... of Iclusig ® (ponatinib).  Funding of the first ... $50 million each, with the initial amount having already ...
(Date:7/29/2015)... Touro College has announced that it is supporting ... of five media marijuana licenses to be issued by the ... (DOH).  If CanniCare is selected, Touro would ... "Our college is supportive of medicinal development and research," ... College System. "There is still a great deal of research ...
Breaking Medicine Technology:Klinischer Nachweis erbracht, dass L. reuteri Probiotikum von Nutraceutix den Darm-Insulinmetabolismus moduliert 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 4PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 5Touro College Announces Support for CanniCare's Medical Cannabis License Application 2
... 2011 Curemark, LLC , ( www.curemark.com ), a ... neurological diseases, announced that the company has completed its targeted ... its autism treatment. Curemark has reached its targeted ... are participating in the CM-AT Phase III trial at 18 ...
... 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... tCGM System as a non-invasive, wireless, transdermal continuous glucose ... transdermal drug delivery, today announced results for the year ... 10-K is available through Echo,s website at www.echotx.com ...
Cached Medicine Technology:Curemark Completes Enrollment of Phase III Autism Trials 2Echo Therapeutics Announces 2010 Financial Results 2Echo Therapeutics Announces 2010 Financial Results 3Echo Therapeutics Announces 2010 Financial Results 4
(Date:7/29/2015)... , ... July 29, 2015 , ... ... on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that ... and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline ...
(Date:7/29/2015)... ... July 29, 2015 , ... The ... a five-year period, expiring November 30, 2019, during its recent meeting. , The ... application demonstrating the program’s compliance with the NCCA’s Standards for the Accreditation of ...
(Date:7/29/2015)... ... July 29, 2015 , ... CrossFit 269, offering a ... to Kalamazoo Strength & Conditioning. , The name change coincides with the release ... our training center over the past three years,” according to Jack Kelly, the ...
(Date:7/29/2015)... ... , ... Today marks a significant achievement in bringing new monies into early ... led by a group of experienced investors, has tapped into an investor community passionate ... be a part of the fund. The Sofia Fund II is now closed ...
(Date:7/29/2015)... ... ... National UV Awareness Month, and in honor of this month, Dr. Melda Isaac of MI-Skin ... the sun, as well as how to best treat existing sun damage. Sun damage can ... conditions in America. Many people do not protect their skin sufficiently when going out in ...
Breaking Medicine News(10 mins):Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Sofia Fund Surpasses Investor Goals 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3
... 13 The Traumatic,Brain Injury Family Caregiver Panel, ... meeting in Silver Spring, MD on June 17 ... on matters needed to continue,dissemination of the Traumatic ... the public regarding this issue., Congress directed ...
... Virginia Distributor Fight for Health Care,and Livable Wages, ... the,West Virginia distributor of Miller and Coors beers ... bars and restaurants today. The workers say,they want ... West,Virginia distributor, Capitol Beverage Company, that would hike ...
... CardioDynamics (Nasdaq:,CDIC), the innovator and leader of ... and Internet webcast for Tuesday, July 1,2008, at ... results for,second quarter 2008. The call will be ... Chief Financial Officer, Steve,Loomis. A press release announcing ...
... of bacteria that causes syphilis may hold clinical, ... in Atlanta have found. , The ... identified in the acidic repeat protein (ARP) gene ... Treponema pallidum subspecies. The study was published online ...
... Digirad Corporation,(Nasdaq: DRAD ), a leading ... physicians, offices, hospitals and imaging centers, today,announced that ... CapStone,Investments, Second Annual Small-Cap Investor Conference to be ... Milwaukee., Casner,s 30-minute presentation, including Q&A, is ...
... HILL, N.C., June 13 Long and costly ... to,maximize limited staff and resources to the development ... companies are integrating,commercial insights earlier and earlier into ... and target promising compounds, reduce development cycle,time, focus ...
Cached Medicine News:Health News:UPDATE: Defense Health Board Traumatic Brain Injury Family Caregivers Panel 2Health News:West Virginia Teamsters Kick Off 'Miller Beer is Tasteless' Protests 2Health News:CardioDynamics Announces Second Quarter 2008 Conference Call and Webcast 2Health News:Emory study of syphilis bacteria yields valuable diagnostic tool 2Health News:Digirad Corporation to Present at CapStone Small-Cap Investor Conference 2Health News:Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence 2
... relieve low back discomfort. Strong mesh elastic ... comfortable, custom fit. Optional metal stays may ... spine. Wide elastic adjustment panels provide varying ... easily accessed and adjusted. Simple hood and ...
... Newport® Hip Management Systems are designed and ... orthosis for your patients. Innovative new options ... is built on the most successful patented ... the adjustable clamping disk design and the ...
... Pelvic Brace is the solution to the ... off-the-shelf brace fits like a custom and ... minutes. The Bledsoe Simple Pelvic Brace limits ... and adduction in 15 increments from -30 ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: